Long-acting amylin receptor agonist and pharmaceutical composition thereof
PK144804BActive Publication Date: 2026-10-20ELI LILLY & CO
0 Cites 0 Cited by
Patent Information
- Application Number
- PK202200120
- Authority / Receiving Office
- PK · PK
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2022-02-28
- Publication Date
- 2026-10-20
Abstract
The present disclosure relates to long acting amylin receptor agonist comprising of Xaa1-C-Xaa3-TATCAT-Xaa10-Xaa11-Xaa12-AE-Xaa15-LVRSS-Xaa21-Xaa22-FGP-Xaa26-LPPTEVGSNTY (SEQ ID NO: 14), wherein Xaa1 is K or γE; Xaa3 is E, N, or G; Xaa10 is G or Q; Xaa11 is Orn or K; Xaa12 is L or αMeL; Xaa15 is αMeF or F; Xaa21 is N or H; Xaa22 is NMeD, NMeN, or N; and Xaa26 is I or K. It relates to the compound which is therapeutically effective for the treatment of diabetes, obesity and / or chronic weight management, dyslipidemia and / or NASH by agonizing the amylin receptor and can lower food intake, body weight, glucose and / or triglycerides. It further discloses pharmaceutical composition containing the claimed compound.
Need to check novelty before this filing date? Find Prior Art
